Events & Presentations
Board of Directors
Historic Stock Lookup
Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
October 20, 2017 | Press Release
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
September 25, 2017 | Press Release
Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02
September 12, 2017 | Press Release
Why did you choose to become the CEO of Galectin Therapeutics?
Are you conducting clinical trials with GR-MD-02? What results have you seen so far?
Can you give me a quick overview of Galectin Therapeutics and the opportunity it sees for GR-MD-02?
Why are the results of the GR-MD-02 psoriasis study so promising?
Why is the NASH-CX trial so important?
See all videos
Galectin Therapeutics, Inc.
Financial Tear Sheet
Filings & Reports
Stock price updates every 30 minutes.
Latest Corporate Presentation
Media Fact Sheet
Corporate Fact Sheet
© 2017 Galectin Therapeutics Inc. - All Rights Reserved
Compassionate Use Policy
Disclaimer: This site may contain